Brief: Acasti Submits Pivotal Gtx-104 Phase 3 Safety Study Protocol With FDA

Grace Therapeutics

08/05/2023 15:31

May 8 (Reuters) - Acasti Pharma Inc  ACST.O :
    * ACASTI SUCCESSFULLY SUBMITS PIVOTAL GTX-104 PHASE 3 SAFETY
STUDY
PROTOCOL WITH FDA AND IMPLEMENTS STRATEGIC REALIGNMENT PLAN THAT
EXTENDS PROJECTED CASH RUNWAY THROUGH CALENDAR Q2 2025
    * ACASTI PHARMA INC: STRATEGIC REALIGNMENT PRIORITIZES
GTX-104
    * ACASTI PHARMA INC: SUBMITS GTX-104 PIVOTAL PHASE 3
PROTOCOL IND
AMENDMENT TO FDA WITH EXPECTATION FOR FIRST PATIENT DOSED IN
CALENDAR Q4 2023
    * ACASTI PHARMA INC: EXPECTS TO EXTEND CASH RUNWAY THROUGH A
POTENTIAL NEW DRUG APPLICATION (NDA) FILING FOR GTX-104
    * ACASTI PHARMA : EVALUATION OF STRATEGIC ALTERNATIVES TO
MAXIMIZE
VALUE OF DE-PRIORITIZED PIPELINE ASSETS INCLUDING OUT-LICENSING
OR SALE
    * ACASTI PHARMA INC: OVER TIME DISCONTINUING ITS OPERATIONS
IN
CANADA, AND HAS PROCEEDED TO LAY OFF SUBSTANTIALLY ALL ITS
WORKFORCE

Source text for Eikon:  ID:nPnbGzFh5a 
Further company coverage:  ACST.O 

 ((Reuters.Briefs@thomsonreuters.com;))